| Literature DB >> 22522395 |
Yih Yih Kok1, Lim Yang Mooi, Kartini Ahmad, Mohd Aspollah Sukari, Nashriyah Mat, Mawardi Rahmani, Abdul Manaf Ali.
Abstract
Girinimbine, a carbazole alkaloid isolated from the stem bark of Murraya koenigii was tested for the in vitro anti-tumour promoting and antioxidant activities. Anti-tumour promoting activity was determined by assaying the capability of this compound to inhibit the expression of early antigen of Epstein-Barr virus (EA-EBV) in Raji cells that was induced by the tumour promoter, phorbol 12-myristate 13-acetate. The concentration of this compound that gave an inhibition rate at fifty percent was 6.0 µg/mL and was not cytotoxic to the cells. Immunoblotting analysis of the expression of EA-EBV showed that girinimbine was able to suppress restricted early antigen (EA-R). However, diffused early antigen (EA-D) was partially suppressed when used at 32.0 µg/mL. Girinimbine exhibited a very strong antioxidant activity as compared to a-tocopherol and was able to inhibit superoxide generation in the 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced differentiated premyelocytic HL-60 cells more than 95%, when treated with the compound at 5.3 and 26.3 µg/mL, respectively. However girinimbine failed to scavenge the stable diphenyl picryl hydrazyl (DPPH)-free radical.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22522395 PMCID: PMC6268782 DOI: 10.3390/molecules17044651
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Girinimbine.
Figure 2Effect of girinimbine on the early antigen (EA) of Epstein-Barr virus activation and the viability of Raji cells.
Figure 3Effects of different concentrations of girinimbine on the synthesis of EBV-early protein diffuse (EA-D) (bottom arrow) and restricted (EA-R) (top arrow) from Raji cells treated with phorbol 12-myristate 13-acetate (PMA, 0.05 µM) and sodium-n-butyrate (3 mM) by immunoblotting analysis. Lane 1 was the pre-stained SDS-PAGE standard, mid-range marker. Lane 2 is the untreated Raji cells (C1), Lane 3 is sodium-n-butyrate treated Raji cells (C2), Lane 4 is PMA and sodium-n-butyrate treated Raji cells (C3), Lanes 5 to 10 are Raji cells treated with girinimbine (1 to 32 µg/mL).
Figure 4Antioxidant activity of girinimbine measured by FTC method.
Figure 5Inhibitory effect of girinimbine on the superoxide generation in differentiated HL60 cells.